09 Jul 2026 Recon: White House reviewing 3 candidates for FDA chief; GSK exits Alector deal after Alzheimer’s, dementia flops Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
07 Jul 2026 Recon: Vertex buys Crinetics for $10B; EMA fast tracks Revolution’s metastatic pancreatic cancer drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
06 Jul 2026 Recon: Novartis to acquire Myricx Bio for $1.1B; Republican lawmakers press FDA to ensure trials are diverse Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
02 Jul 2026 Recon: FDA approves Vertex gene therapy for children with sickle cell disease; Judge blocks Colorado price cap on Amgen’s Enbrel Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
30 Jun 2026 Recon: FDA rejects Unicycive's kidney disease therapy; Top FDA gene therapy regulator to step down Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
29 Jun 2026 Recon: FDA will review generic GLP-1; India floats faster licensing for some devices Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
25 Jun 2026 Recon: FDA grants breakthrough designation to gen AI radiology tools; Oncology paper retraction casts doubt on China research Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
23 Jun 2026 Recon: Pfizer’s experimental therapy falters in lung cancer study; European patient access to new drugs worsens Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
22 Jun 2026 Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy Recon
18 Jun 2026 Recon: Biogen to acquire RayThera for $1B; FDA approves first generic version Roche flu drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
